Aardvark Therapeutics raised $85 million for its obesity-related drug and to support a potential IPO this year.
Biogen said on Thursday that the European Commission has granted marketing authorization under exceptional circumstances for ...
Commonly known as Lou Gehrig's disease, ALS affects roughly 60,000 people in the U.S. and Europe. Biogen and Ionis' drug, BIIB105, did not succeed in significantly reducing neurodegeneration or ...
Biogen and Ionis Pharmaceuticals are stopping development of an experimental drug for ALS following new clinical trial results that didn’t meet the companies’ expectations. The trial ...
The drug, an antisense oligonucleotide (ASO ... viewing it as a significant development for the ALS community. Through Biogen's early access program, approximately 330 people with SOD1-ALS ...
Biogen (Nasdaq: BIIB) has announced European approval for Qalsody (tofersen), for certain amyotrophic lateral sclerosis (ALS) patients, under exceptional circumstances.
Biogen (NASDAQ:BIIB) has received EU regulatory approval for its drug Qalsody, also known as tofersen, for the treatment of ALS associated with a mutation in the superoxide dismutase 1 gene ...
Biogen receives European marketing authorization for Qalsody to treat a rare, genetic form of ALS: Cambridge, Massachusetts Saturday, June 1, 2024, 10:00 Hrs [IST] Biogen Inc. ann ...
London: Biogen said on Thursday that the European Commission has granted marketing authorisation under exceptional circumstances for its amyotrophic lateral sclerosis (ALS) drug Qalsody.
emphasized the company's commitment to bringing QALSODY to SOD1-ALS patients throughout Europe as quickly as possible. QALSODY has also been approved in the United States, and Biogen is in discussions ...